Systematic (IUPAC) name
Acetamidohexanoyl]amino}-9-benzyl- 6-(3-carbamimidamidopropyl)-12- (1H-imidazol-5-ylmethyl)-3-(1H-indol- 3-ylmethyl)-2,5,8,11,14,17-hexaoxo- 1,4,7,10,13,18-hexaazacyclotricosane -23-carboxylic acid
CAS number 189691-06-3
ATC code ?
Mol. mass 1025.2
SMILES eMolecules & PubChem
Bremelanotide (pronounced /brɛ ˌmɛ læ noʊ ˈtаɪd/ bremelanotide-pronunciation.ogg bremelanotide (help·info)) (formerly PT-141) is a compound under drug
development by Palatin Technologies as a treatment for hemorrhagic shock and reperfusion injury. It functions by activating the melanocortin receptors MC1R and MC4R, to modulate inflammation and limiting ischemia.  It was originally developed for use in treating sexual dysfunction but this application was discontinued in 2008, after concerns were raised over adverse side effects
of increased blood pressure.
* 1 Development
* 2 Structure
* 3 See also
* 4 References
* 5 External links
Originally, the peptide Melanotan II
, that bremelanotide was developed from, was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten
original male volunteer test subjects.
In studies, bremelanotide was shown to induce lordosis in an animal model  and be effective in treating sexual dysfunction in both
men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system
A Phase III clinical trial was scheduled to begin in the first half of 2007, but was delayed until August 2007. On August 30, Palatin announced that the U.S. Food and Drug Administration had expressed serious concerns regarding the risk/benefit ratio of bremelanotide with regards to the side effect
of increased blood pressure. The FDA stated that they would consider alternate uses for bremelanotide, including as a treatment for individuals who do not respond to more established ED treatments. However, On May 13, 2008, Palatin Technologies announced it "has discontinued development of Bremelanotide for the treatment of male and female sexual dysfunction" however they concurrently announced plans to develop it as a treatment for hemorrhagic shock instead.  The company additionally announced intentions to focus its attention on another compound, PL-6983, that causes lower blood pressure in animal models. 
Bremelanotide is a cyclic hepta-peptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates the melanocortin receptors MC3-R and MC4-R in the central nervous system. It has the amino acid
sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH or cyclo-[Nle4, Asp5, D-Phe7, Lys10]alpha-MSH-(4-10). It is a metabolite of Melanotan II that lacks the C-terminal amide function.
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Palatin Technologies, Inc., Cranbury, New Jersey 08512, USA. firstname.lastname@example.org
OBJECTIVES: To evaluate the safety and pharmacodynamic effect of co-administration of subtherapeutic doses of PT-141, a cyclic heptapeptide melanocortin analogue, and sildenafil to patients with erectile dysfunction. METHODS: Nineteen patients with erectile dysfunction who were responders to either Viagra or Levitra by self-report were given 25 mg sildenafil and 7.5 mg intranasal PT-141, 25 mg sildenafil and an intranasal placebo spray, and a placebo tablet and an intranasal placebo spray in a randomized cross-over design. Erectile activity in response to two 30-minute episodes of visual sexual stimulation was assessed by RigiScan during a 6-hour postdose period. RESULTS: The erectile response induced by co-administration of PT-141 and sildenafil was significantly greater than the response elicited by administration of sildenafil alone. Co-administration of PT-141 and sildenafil was safe and well-tolerated and did not result in new adverse events or adverse events that were increased in frequency or severity compared with monotherapy. CONCLUSIONS: Co-administration of intranasal PT-141 and a phosphodiesterase type 5 inhibitor may constitute a treatment alternative for patients in whom higher doses of a single therapy are not effective or well tolerated.
PMID: 15833522 [PubMed - indexed for MEDLINE]
956Vette added 3 Minutes and 19 Seconds later...
What is Bremelanotide (PT-141)?
Bremelanotide (formerly PT-141) is the generic term for a new medication for use in treating sexual dysfunction in men (erectile dysfunction or impotence) as well as sexual dysfunction in women (sexual arousal disorder). It is a synthetic aphrodisiac. Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire.
Originally, the peptide Melanotan II that bremelanotide was developed from was tested as a sunless tanning agent. In initial testing, Melanotan II did induce tanning but additionally caused sexual arousal and spontaneous erections as unexpected side effects in eight out of the ten original male volunteer test subjects. In clinical studies, bremelanotide has been shown to be effective in treating male sexual and erectile dysfunction as well as female sexual dysfunction. It is currently being tested by Palatin Technologies.
Bremelanotide is a cyclic hepta-peptide lactam analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that activates the melanocortin receptors MC3-R and MC4-R in the central nervous system. It has the amino acid sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH or cyclo-[Nle4, Asp5, D-Phe7, Lys10]alpha-MSH-(4-10). PT-141 is a metabolite of Melanotan II that lacks the C-terminal amide function. Its molecular formula is C50H68N14O10 with a molecular weight of 1025.2.
In the United States it is currently in a Phase III clinical trial.
Are these nasal? Oral, Injectable?
Currently the nasal and oral routes have not been made efficient. PT-141 is a sterile injectable made for sub-q injection, like insulin.
What's the dosing schedule...how much do I take?
.5mg-2mg is the range which people dose. Taking 2-4 hours before game time is ideal. The window of opportunity is very unique.
Say you had a dinner and movie arranged. Taking before dinner may be the best route, however during the climax of the movie may interfere with one of your own…read between the lines there
Is there any reconstituting involved?
Yes and bacteriostatic water is the recommended solvent here. To mix the vial with bact water, take one syringe (BD Ultrafine II 1cc or 1/3 cc are excellent and I recommend them) and grab your vial of bacteriostatic water. If using a 1 cc syringe (100 units), use the syringe to withdraw 1 full ml (1cc) and inject that into the vial of PT-141 through the rubber. Be sure to aim the needle towards the glass, so that it will trickle down and not harm the peptide. Swirl the vial to thoroughly mix and let the peptide dissolve. The key here is to be gentle. Say you had the vial of PT-141 stored in the freezer, move the vial of PT-141 to fridge for an overnight stay. Then you are ready the next day to reconstitute the same temperature refrigerated bact water with the PT-141 in the most efficient manner. Just some tricks of the trade here.
So now you have 100 units (1cc) of bacteriostatic water mixed with 10 mg of PT-141 in your vial ready to go. A 1mg dose would be 10 units or .1ml (.1cc). Make sense? Hope so.
How is it stored?
The lyophilized powder (freeze dried state) can be stored in the freezer or refrigerator. Once reconstituted (mixed with water) it will be good for a month in the refrigerator before it begins to degrade.
Does this help give erections or just put you in the mood?
“With PT-141, you feel good, not only sexually aroused,” reported anonymous patient 007, a participant in a Phase 2 trial, “you feel younger and more energetic.” Said another patient: “It helped the libido. So you have the urge and the desire. . . . You get this humming feeling; you’re ready to take your pants off and go.” And another: “Twice my wife and I had sex twice in one night. I came in [to work] and I just raved about it: ‘Jesus, guys . . . 58 years old and you don’t do that.’ ” Tales of pharmaceutically induced sexual prowess among 58-year-olds are common enough in the age of the Little Blue Pill, but they don’t typically involve quite so urgent a repertoire of humming, throbbing, tingling, and double-dipping. Or as patient 128 put it: “My wife knows. She can tell the difference between Viagra and PT-141.”
The precise mechanisms by which PT-141 does its job remain unclear, but the rough idea is this: Where Viagra acts on the circulatory system, helping blood flow into the penis, PT-141 goes straight to the brain itself. And there it goes to work, switching on the same neural circuitry that lights up when a person actually, you know, wants to.
Basically this takes men back to middle school. You may find yourself in a similar situation as you were in 8th grade science class with the teacher bent over helping the student in front of you. It may be necessary to do a “tuck up” if at the office…especially at the public pool!
Women state that the sensation given from injecting PT-141 is like being in heat! One colleague in particular stated that she didn’t know what was going on…but she had wanted “it” all day long after dosing the night before.